Compare · PULM vs SVRA
PULM vs SVRA
Side-by-side comparison of Pulmatrix Inc. (PULM) and Savara Inc. (SVRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PULM and SVRA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- SVRA is the larger of the two at $987.3M, about 197.3x PULM ($5.0M).
- PULM has been more active in the news (8 items in the past 4 weeks vs 4 for SVRA).
- SVRA has more recent analyst coverage (12 ratings vs 0 for PULM).
- Company
- Pulmatrix Inc.
- Savara Inc.
- Price
- -
- -
- Market cap
- $5.0M
- $987.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 8
- 4
- Recent ratings
- 0
- 12
Pulmatrix Inc.
Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal infections and allergic/hypersensitivity reactions to fungus in patients with severe lung diseases comprising asthma, cystic fibrosis, and allergic bronchopulmonary aspergillosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with lung cancer and chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Savara Inc.
Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Latest PULM
- Pulmatrix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger
- Eos SENOLYTIX’s PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International Conference
- SEC Form 425 filed by Pulmatrix Inc.
- Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study
- SEC Form 425 filed by Pulmatrix Inc.
- SEC Form 8-K filed by Pulmatrix Inc.
- SEC Form 424B3 filed by Pulmatrix Inc.
- SEC Form EFFECT filed by Pulmatrix Inc.
- Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse
Latest SVRA
- SEC Form SCHEDULE 13G filed by Savara Inc.
- Savara Announces New Employment Inducement Grant
- H.C. Wainwright resumed coverage on Savara with a new price target
- SEC Form 10-Q filed by Savara Inc.
- Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
- Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
- Analyst initiated coverage on Savara with a new price target
- Chief Commercial Officer Parker Braden C. covered exercise/tax liability with 29,323 shares, decreasing direct ownership by 28% to 75,677 units (SEC Form 4)
- Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
- Savara Announces New Employment Inducement Grant